Real-time Estimate
Cboe BZX
10:44:11 2024-06-03 am EDT
|
5-day change
|
1st Jan Change
|
3.865
USD
|
+12.68%
|
|
+17.69%
|
+116.10%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,002
|
448.2
|
141.1
|
330.9
|
641.5
|
-
|
-
|
Enterprise Value (EV)
1 |
750.9
|
299.1
|
91.21
|
227.5
|
578.7
|
494.8
|
307.7
|
P/E ratio
|
-7.81
x
|
-2.51
x
|
-0.6
x
|
-1.84
x
|
-8.15
x
|
-6.89
x
|
-8.33
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
56.4
x
|
21.4
x
|
54.8
x
|
108
x
|
14.6
x
|
EV / Revenue
|
-
|
-
|
36.5
x
|
14.7
x
|
49.5
x
|
83.5
x
|
7.02
x
|
EV / EBITDA
|
-17.5
x
|
-1.73
x
|
-0.73
x
|
-3.2
x
|
-7.25
x
|
-5.65
x
|
8.9
x
|
EV / FCF
|
-24.4
x
|
-2.26
x
|
-0.84
x
|
-2.96
x
|
-5.51
x
|
-4.63
x
|
-4.88
x
|
FCF Yield
|
-4.1%
|
-44.2%
|
-120%
|
-33.8%
|
-18.1%
|
-21.6%
|
-20.5%
|
Price to Book
|
3.99
x
|
4.7
x
|
105
x
|
4.42
x
|
-68.6
x
|
-68.6
x
|
-
|
Nbr of stocks (in thousands)
|
37,761
|
38,474
|
62,442
|
186,960
|
187,018
|
-
|
-
|
Reference price
2 |
26.54
|
11.65
|
2.260
|
1.770
|
3.430
|
3.430
|
3.430
|
Announcement Date
|
3/3/21
|
3/31/22
|
3/28/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
2.502
|
15.45
|
11.7
|
5.922
|
43.82
|
EBITDA
1 |
-42.99
|
-172.8
|
-124.9
|
-71.07
|
-79.83
|
-87.55
|
34.56
|
EBIT
1 |
-43
|
-173.3
|
-162.4
|
-72.44
|
-91.51
|
-97.75
|
-91.04
|
Operating Margin
|
-
|
-
|
-6,492.69%
|
-468.83%
|
-782.09%
|
-1,650.59%
|
-207.74%
|
Earnings before Tax (EBT)
1 |
-60.01
|
-174.5
|
-166
|
-111.6
|
-90.59
|
-101.9
|
-89.43
|
Net income
1 |
-60.01
|
-174.5
|
-166
|
-111.6
|
-90.59
|
-101.9
|
-84.55
|
Net margin
|
-
|
-
|
-6,635.25%
|
-722.06%
|
-774.16%
|
-1,720.36%
|
-192.94%
|
EPS
2 |
-3.400
|
-4.640
|
-3.780
|
-0.9600
|
-0.4210
|
-0.4978
|
-0.4120
|
Free Cash Flow
1 |
-30.81
|
-132.3
|
-109
|
-76.89
|
-105
|
-106.9
|
-63.02
|
FCF margin
|
-
|
-
|
-4,356.87%
|
-497.62%
|
-897.53%
|
-1,804.57%
|
-143.8%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/3/21
|
3/31/22
|
3/28/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
2.502
|
4.706
|
2.395
|
4.746
|
3.604
|
3.411
|
2.424
|
2.439
|
2.521
|
2.035
|
2.442
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-49.72
|
-49.27
|
-32.98
|
-25.07
|
-55.12
|
-16.56
|
-23.38
|
-15.63
|
-16.25
|
-24.33
|
-21.9
|
-22.28
|
-22.18
|
-25.15
|
-25.8
|
Operating Margin
|
-
|
-
|
-
|
-
|
-2,203.04%
|
-351.87%
|
-976.37%
|
-329.41%
|
-450.78%
|
-713.28%
|
-903.24%
|
-913.53%
|
-879.87%
|
-1,235.65%
|
-1,056.52%
|
Earnings before Tax (EBT)
1 |
-50.39
|
-50.11
|
-33.87
|
-26.31
|
-55.72
|
-17.62
|
-24.6
|
-117.1
|
47.74
|
-24.06
|
-22.37
|
-22.58
|
-22.69
|
-25.68
|
-26
|
Net income
1 |
-50.39
|
-50.11
|
-33.87
|
-26.31
|
-55.72
|
-17.62
|
-24.6
|
-117.1
|
47.74
|
-24.06
|
-22.37
|
-22.58
|
-22.69
|
-25.68
|
-26
|
Net margin
|
-
|
-
|
-
|
-
|
-2,227.14%
|
-374.46%
|
-1,027.06%
|
-2,467.07%
|
1,324.67%
|
-705.39%
|
-922.88%
|
-925.95%
|
-900.08%
|
-1,261.58%
|
-1,064.64%
|
EPS
2 |
-1.320
|
-1.310
|
-0.8400
|
-0.6400
|
-0.9900
|
-0.2800
|
-0.3800
|
-0.9300
|
0.9200
|
-0.1000
|
-0.1060
|
-0.1060
|
-0.1040
|
-0.1229
|
-0.1200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/31/22
|
5/16/22
|
8/11/22
|
11/8/22
|
3/28/23
|
5/11/23
|
8/14/23
|
11/14/23
|
3/19/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
251
|
149
|
49.9
|
103
|
62.7
|
147
|
334
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-30.8
|
-132
|
-109
|
-76.9
|
-105
|
-107
|
-63
|
ROE (net income / shareholders' equity)
|
-47.8%
|
-101%
|
-345%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
6.650
|
2.480
|
0.0200
|
0.4000
|
-0.0500
|
-0.0500
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.08
|
15.3
|
20.6
|
3.87
|
4.52
|
3.93
|
5.23
|
Capex / Sales
|
-
|
-
|
824.1%
|
25.04%
|
38.65%
|
66.29%
|
11.92%
|
Announcement Date
|
3/3/21
|
3/31/22
|
3/28/23
|
3/19/24
|
-
|
-
|
-
|
Last Close Price
3.43
USD Average target price
6.95
USD Spread / Average Target +102.62% Consensus |
1st Jan change
|
Capi.
|
---|
| +116.10% | 641M | | +49.74% | 54.63B | | -5.38% | 39.92B | | +37.32% | 38.82B | | +14.65% | 26.86B | | -12.56% | 26.22B | | -21.86% | 18.78B | | +26.12% | 12.21B | | +1.81% | 12.16B | | +26.69% | 11.94B |
Other Biotechnology & Medical Research
|